These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22304541)

  • 1. Treatment-emergent adverse events associated with atypical antipsychotics.
    Cha DS; McIntyre RS
    Expert Opin Pharmacother; 2012 Aug; 13(11):1587-98. PubMed ID: 22304541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder.
    McIntyre RS; Konarski JZ
    J Clin Psychiatry; 2005; 66 Suppl 3():28-36. PubMed ID: 15762832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of bipolar mania with atypical antipsychotics.
    Chengappa KN; Suppes T; Berk M
    Expert Rev Neurother; 2004 Nov; 4(6 Suppl 2):S17-25. PubMed ID: 16279862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotic tolerability and switching strategies in bipolar disorder.
    Liauw SS; McIntyre RS
    Expert Opin Pharmacother; 2010 Dec; 11(17):2827-37. PubMed ID: 20726821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
    Keck PE; McElroy SL; Strakowski SM; Soutullo CA
    J Clin Psychiatry; 2000; 61 Suppl 4():33-8. PubMed ID: 10739329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotics and the burden of disease.
    Simpson GM
    Am J Manag Care; 2005 Sep; 11(8 Suppl):S235-41. PubMed ID: 16180961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents.
    Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 4():26-36. PubMed ID: 18533766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic drug toxicology in children.
    Caccia S; Clavenna A; Bonati M
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):591-608. PubMed ID: 21401439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of atypical antipsychotics in mood disorders.
    Yatham LN
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S9-14. PubMed ID: 12832944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatments for bipolar disorder: safety and adverse effect profiles.
    Marken PA; Pies RW
    Ann Pharmacother; 2006 Feb; 40(2):276-85. PubMed ID: 16403851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.
    Jafari S; Fernandez-Enright F; Huang XF
    J Neurochem; 2012 Feb; 120(3):371-84. PubMed ID: 22103329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.
    Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE
    Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
    Thomas P
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reasons for switching between antipsychotics in daily clinical practice.
    Hugenholtz GW; Heerdink ER; Meijer WE; Stolker JJ; Egberts AC; Nolen WA
    Pharmacopsychiatry; 2005 May; 38(3):122-4. PubMed ID: 15902582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy, safety, and tolerability of antipsychotics in the elderly.
    Maixner SM; Mellow AM; Tandon R
    J Clin Psychiatry; 1999; 60 Suppl 8():29-41. PubMed ID: 10335669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE).
    Fischer-Barnicol D; Lanquillon S; Haen E; Zofel P; Koch HJ; Dose M; Klein HE;
    Neuropsychobiology; 2008; 57(1-2):80-7. PubMed ID: 18515977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.